MacroGenics (MGNX) Projected to Post Quarterly Earnings on Thursday

MacroGenics (NASDAQ:MGNX) is projected to post its quarterly earnings results after the market closes on Thursday, March 20th. Analysts expect MacroGenics to post earnings of ($0.23) per share and revenue of $34.17 million for the quarter. Individual interested in registering for the company’s earnings conference call can do so using this link.

MacroGenics Stock Down 1.8 %

Shares of NASDAQ MGNX opened at $2.18 on Tuesday. The firm’s 50-day moving average price is $2.75 and its two-hundred day moving average price is $3.26. MacroGenics has a 52-week low of $2.14 and a 52-week high of $19.54. The stock has a market capitalization of $136.82 million, a P/E ratio of -1.38 and a beta of 2.12.

MacroGenics Company Profile

MacroGenics, Inc, a biopharmaceutical company, develops, manufactures, and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens.